Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bisphosphocins - Lakewood Amedex

Drug Profile

Research programme: bisphosphocins - Lakewood Amedex

Alternative Names: Bisphosphocin Nu-8; Bisphosphocins; Nu 2; Nu 4; Nu 5; Nu 8; NuBiotics - Lakewood-Amedex; Nubiotics research programme - Oligos Etc.

Latest Information Update: 24 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oligos Etc.
  • Developer Lakewood Amedex
  • Class Anti-infectives; Antibacterials; Antifibrotics; Nucleotides; Small molecules
  • Mechanism of Action Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis; Infections; Urinary tract infections

Most Recent Events

  • 24 May 2019 Lakewood Amedex announces intention to submit an IND application with the US FDA for Urinary tract infections (Complicated) (IV) in 2019(Lakewood Amedex pipeline, May 2019)
  • 24 May 2019 Lakewood Amedex plans a phase I/IIa trial for Urinary tract infections (Complicated) (IV) in H2 2019 (Lakewood Amedex pipeline, May 2019)
  • 24 May 2019 Lakewood Amedex has patent protection for bisphosphocin technology in World (Lakewood Amedex pipeline, May 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top